MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis

Prosperini L.
Kinkel R. P.
Miravalle A. A.
Iaffaldano P.
Fantaccini S.

January 2019

Background: Natalizumab (NTZ) is sometimes discontinued in patients with multiple sclerosis, mainly ...

Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients

Kerbrat, Anne
Le Page, Emmanuelle
Leray, Emmanuelle
Anani, T.
Coustans, M.
Desormeaux, C.
Guiziou, C.
Kassiotis, P.
Lallement, F.
Laplaud, David ,
Diraison, P.
Rouhart, F.
Sartori, E.
Wardi, R.
Wiertlewski, S.
Edan, Gilles

January 2011

International audienceBACKGROUND: In order to reduce the risk of progressive multifocal leucoencepha...

Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients

Kerbrat, A.
Le Page, E.
Leray, Emmanuelle
Anani, T.
Coustans, M.
Desormeaux, C.
Guiziou, C.
Kassiotis, P.
Lallement, F.
Laplaud, D.
Diraison, P.
Rouhart, F.
Sartori, E.
Wardi, R.
Wiertlewski, S.
Edan, Gilles

September 2011

International audienceBackground: In order to reduce the risk of progressive multifocal leucoencepha...

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study

Fox, Robert J.
Cree, Bruce A.C.
Sèze, Jerome De
Gold, Ralf
Hartung, Hans-Peter
Jeffery, Douglas
Kappos, Ludwig
Kaufman, Michael
Montalbán Gairín, Xavier
Weinstock-Guttman, Bianca
Anderson, Britt
Natarajan, Amy
Ticho, Barry
Duda, Petra
Martínez Yélamos, Sergio
RESTORE

June 2021

Objective: RESTORE was a randomized, partially placebo-controlled exploratory study evaluating multi...

Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE

Kaufman, M
Cree, BAC
De Sèze, J
Fox, RJ
Gold, R
Hartung, H-P
Jeffery, D
Kappos, L
Montalbán, X
Weinstock-Guttman, B
Ticho, B
Duda, P
Pace, A
Campagnolo, D

November 2014

The objective of this study is to characterize the timing and extent of radiologic MS disease recurr...

Observations during an elective interruption of natalizumab treatment: a post-marketing study

G. Borriello
Luca Prosperini
F. Marinelli
F. Fubelli
Carlo Pozzilli

January 2011

In this prospective post-marketing study, 21 patients with multiple sclerosis treated with natalizum...

Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers

LO RE, Marianna
Capobianco, M.
RAGONESE, Paolo
REALMUTO, Sabrina
Malucchi, S.
Berchialla, P.
SALEMI, Giuseppe
Bertolotto, A.

January 2015

Introduction: Natalizumab (NTZ) discontinuation can be followed by multiple sclerosis (MS) disease r...

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study)

Clerico, Marinella
Schiavetti, Irene
De Mercanti, Stefania F
Piazza, Federico
Gned, Dario
Brescia Morra, Vincenzo
Lanzillo, Roberta
Ghezzi, Angelo
Bianchi, Anna
Salemi, Giuseppe
Realmuto, Sabrina
Sola, Patrizia
Vitetta, Francesca
Cavalla, Paola
Paolicelli, Damiano
Trojano, Maria
Sormani, Maria Pia
Durelli, Luca
Ferraro, Diana

January 2014

IMPORTANCE The evaluation of therapeutic choices is needed after 24 doses of natalizumab in patients...

Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

Roos, Izanne
Malpas, Charles
Leray, Emmanuelle
Casey, Romain
Horakova, Dana
Havrdova, Eva Kubala
Debouverie, Marc
Patti, Francesco
de Seze, Jerome
Izquierdo, Guillermo
Eichau, Sara
Edan, Gilles
Prat, Alexandre
Girard, Marc
Ozakbas, Serkan
Grammond, Pierre
Zephir, Helene
Ciron, Jonathan
Maillart, Elisabeth
Mccombe, Pamela Ann
Moreau, Thibault
Amato, Maria Pia
Labauge, Pierre
Bourre, Bertrand
Alroughani, Raed
Buzzard, Katherine
Skibina, Olga
Terzi, Murat
Laplaud, David Axel
Berger, Eric
Slee, Mark
Grand'Maison, Francois
Lebrun-Frenay, Christine
Cartechini, Elisabetta
Soysal, Aysun
Boz, Cavit
Lechner-Scott, Jeannette
Clavelou, Pierre
Stankoff, Bruno
Prevost, Julie
Kappos, Ludwig
Pelletier, Jean
Shaygannejad, Vahid
Yamout, Bassem
Khoury, Samia
Gerlach, Oliver
Spitaleri, Daniele
van Pesch, Vincent
Gout, Olivier
Turkoglu, Recai
Heinzlef, Olivier
Thouvenot, Eric
Castillo-Trivino, Tamara
Bakchine, Serge
Ampapa, Radek
Butler, Ernest Gerard
Wahab, Abir
Macdonell, Richard
Aguera-Morales, Eduardo
Cabre, Philippe
Ben, Nasr Haifa
van der Walt, Anneke
Laureys, Guy
van Hijfte, Liesbeth
Ramo-Tello, Cristina
Maubeuge, Nicolas
Hodgkinson, Suzanne
Sánchez-Menoyo, José Luis
Barnett, Michael
Labeyrie, Celine
Vucic, Steve
Sidhom, Youssef
Gouider, Riadh
Csepany, Tunde
Sotoca, Javier
de Gans, Koen
Al-Asmi, Abdullah
Fragoso, Yara Dadalti
Vukusic, Sandra
Butzkueven, Helmut
Kalincik, Tomas

August 2022

International audienceObjectives: To evaluate the rate of return of disease activity after cessation...

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis.

Prosperini, Luca
Kinkel, Revere
Miravalle, Augusto
Iaffaldano, Pietro
Fantaccini, Simone

January 2019

BACKGROUND: Natalizumab (NTZ) is sometimes discontinued in patients with multiple sclerosis, mainly ...

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis

Prosperini L.
Kinkel R. P.
Miravalle A. A.
Iaffaldano P.
Fantaccini S.

January 2019

Background: Natalizumab (NTZ) is sometimes discontinued in patients with multiple sclerosis, mainly ...

Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients

Kerbrat, Anne
Le Page, Emmanuelle
Leray, Emmanuelle
Anani, T.
Coustans, M.
Desormeaux, C.
Guiziou, C.
Kassiotis, P.
Lallement, F.
Laplaud, David ,
Diraison, P.
Rouhart, F.
Sartori, E.
Wardi, R.
Wiertlewski, S.
Edan, Gilles

January 2011

International audienceBACKGROUND: In order to reduce the risk of progressive multifocal leucoencepha...

Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients

Kerbrat, A.
Le Page, E.
Leray, Emmanuelle
Anani, T.
Coustans, M.
Desormeaux, C.
Guiziou, C.
Kassiotis, P.
Lallement, F.
Laplaud, D.
Diraison, P.
Rouhart, F.
Sartori, E.
Wardi, R.
Wiertlewski, S.
Edan, Gilles

September 2011

International audienceBackground: In order to reduce the risk of progressive multifocal leucoencepha...

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study

Fox, Robert J.
Cree, Bruce A.C.
Sèze, Jerome De
Gold, Ralf
Hartung, Hans-Peter
Jeffery, Douglas
Kappos, Ludwig
Kaufman, Michael
Montalbán Gairín, Xavier
Weinstock-Guttman, Bianca
Anderson, Britt
Natarajan, Amy
Ticho, Barry
Duda, Petra
Martínez Yélamos, Sergio
RESTORE

June 2021

Objective: RESTORE was a randomized, partially placebo-controlled exploratory study evaluating multi...

Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE

Kaufman, M
Cree, BAC
De Sèze, J
Fox, RJ
Gold, R
Hartung, H-P
Jeffery, D
Kappos, L
Montalbán, X
Weinstock-Guttman, B
Ticho, B
Duda, P
Pace, A
Campagnolo, D

November 2014

The objective of this study is to characterize the timing and extent of radiologic MS disease recurr...

Observations during an elective interruption of natalizumab treatment: a post-marketing study

G. Borriello
Luca Prosperini
F. Marinelli
F. Fubelli
Carlo Pozzilli

January 2011

In this prospective post-marketing study, 21 patients with multiple sclerosis treated with natalizum...

Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers

LO RE, Marianna
Capobianco, M.
RAGONESE, Paolo
REALMUTO, Sabrina
Malucchi, S.
Berchialla, P.
SALEMI, Giuseppe
Bertolotto, A.

January 2015

Introduction: Natalizumab (NTZ) discontinuation can be followed by multiple sclerosis (MS) disease r...

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study)

Clerico, Marinella
Schiavetti, Irene
De Mercanti, Stefania F
Piazza, Federico
Gned, Dario
Brescia Morra, Vincenzo
Lanzillo, Roberta
Ghezzi, Angelo
Bianchi, Anna
Salemi, Giuseppe
Realmuto, Sabrina
Sola, Patrizia
Vitetta, Francesca
Cavalla, Paola
Paolicelli, Damiano
Trojano, Maria
Sormani, Maria Pia
Durelli, Luca
Ferraro, Diana

January 2014

IMPORTANCE The evaluation of therapeutic choices is needed after 24 doses of natalizumab in patients...

Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

Roos, Izanne
Malpas, Charles
Leray, Emmanuelle
Casey, Romain
Horakova, Dana
Havrdova, Eva Kubala
Debouverie, Marc
Patti, Francesco
de Seze, Jerome
Izquierdo, Guillermo
Eichau, Sara
Edan, Gilles
Prat, Alexandre
Girard, Marc
Ozakbas, Serkan
Grammond, Pierre
Zephir, Helene
Ciron, Jonathan
Maillart, Elisabeth
Mccombe, Pamela Ann
Moreau, Thibault
Amato, Maria Pia
Labauge, Pierre
Bourre, Bertrand
Alroughani, Raed
Buzzard, Katherine
Skibina, Olga
Terzi, Murat
Laplaud, David Axel
Berger, Eric
Slee, Mark
Grand'Maison, Francois
Lebrun-Frenay, Christine
Cartechini, Elisabetta
Soysal, Aysun
Boz, Cavit
Lechner-Scott, Jeannette
Clavelou, Pierre
Stankoff, Bruno
Prevost, Julie
Kappos, Ludwig
Pelletier, Jean
Shaygannejad, Vahid
Yamout, Bassem
Khoury, Samia
Gerlach, Oliver
Spitaleri, Daniele
van Pesch, Vincent
Gout, Olivier
Turkoglu, Recai
Heinzlef, Olivier
Thouvenot, Eric
Castillo-Trivino, Tamara
Bakchine, Serge
Ampapa, Radek
Butler, Ernest Gerard
Wahab, Abir
Macdonell, Richard
Aguera-Morales, Eduardo
Cabre, Philippe
Ben, Nasr Haifa
van der Walt, Anneke
Laureys, Guy
van Hijfte, Liesbeth
Ramo-Tello, Cristina
Maubeuge, Nicolas
Hodgkinson, Suzanne
Sánchez-Menoyo, José Luis
Barnett, Michael
Labeyrie, Celine
Vucic, Steve
Sidhom, Youssef
Gouider, Riadh
Csepany, Tunde
Sotoca, Javier
de Gans, Koen
Al-Asmi, Abdullah
Fragoso, Yara Dadalti
Vukusic, Sandra
Butzkueven, Helmut
Kalincik, Tomas

August 2022

International audienceObjectives: To evaluate the rate of return of disease activity after cessation...

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis.

Prosperini, Luca
Kinkel, Revere
Miravalle, Augusto
Iaffaldano, Pietro
Fantaccini, Simone

January 2019

BACKGROUND: Natalizumab (NTZ) is sometimes discontinued in patients with multiple sclerosis, mainly ...

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis

Prosperini L.
Kinkel R. P.
Miravalle A. A.
Iaffaldano P.
Fantaccini S.

January 2019

Background: Natalizumab (NTZ) is sometimes discontinued in patients with multiple sclerosis, mainly ...

Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients

Kerbrat, Anne
Le Page, Emmanuelle
Leray, Emmanuelle
Anani, T.
Coustans, M.
Desormeaux, C.
Guiziou, C.
Kassiotis, P.
Lallement, F.
Laplaud, David ,
Diraison, P.
Rouhart, F.
Sartori, E.
Wardi, R.
Wiertlewski, S.
Edan, Gilles

January 2011

International audienceBACKGROUND: In order to reduce the risk of progressive multifocal leucoencepha...

Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients

Kerbrat, A.
Le Page, E.
Leray, Emmanuelle
Anani, T.
Coustans, M.
Desormeaux, C.
Guiziou, C.
Kassiotis, P.
Lallement, F.
Laplaud, D.
Diraison, P.
Rouhart, F.
Sartori, E.
Wardi, R.
Wiertlewski, S.
Edan, Gilles

September 2011

International audienceBackground: In order to reduce the risk of progressive multifocal leucoencepha...

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

Abstract

Extracted data

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

Abstract

Extracted data

Related items

Related items